Prostate SPORE Project 1
Utility of serum and tissue biomarkers for predicting response to androgen deprivation therapy in the population of men with rising PSA following definitive treatment
The majority of men with prostate cancer are now diagnosed with cancers with a low risk of cause-specific mortality.1-2 Such men are most frequently treated with primary definitive therapy including radical prostatectomy, external beam radiotherapy, or interstitial brachytherapy and are followed by regular serum PSA evaluations thereafter. Over a 5 to 10 year period, 15-30% of these men will be observed to have a rising PSA.3, 4, 5
Of this group, some men will have obvious local recurrence or have clinically detectable metastasis, but many will have no other evidence of recurrent prostate cancer other than a rising or detectable PSA. These PSA relapses are conservatively estimated to affect approximately 50,000 men each year, define a rapidly growing population of major clinical and public health significance. The PSA "doubling time" has been identified as a potential surrogate for cause-specific mortality, and is used by some clinicians to determine which of these men deserve adjuvant hormonal ablation, local radiation therapy, or simple observation.6-7
Biomarkers that could predict which of these men would benefit from any additional therapy are clearly needed. Genomic studies on prostate cancer tissue provide a good basis not only for tissue markers but also to identify candidates for potential serum biomarkers. Thus in this project we propose a clinical epidemiology study to evaluate and validate comprehensive tissue biomarker panels and to use data from these arrays to develop serum biomarker panels. We will then test both serum and tissue biomarker panels in a clinical trial intended to improve the care of patients with prostate cancer, and ultimately reduce the suffering and early death associated with prostate cancer progression.
© 2013 Mayo Foundation for Medical Education and Research. All rights reserved.